摘要
免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现极大程度上改变了非小细胞肺癌(nonsmall cell lung cancer, NSCLC)患者的治疗前景,术前新辅助免疫治疗方案作为一种有效、安全的治疗方案逐渐受到重视。然而,新辅助免疫治疗方案相关的研究起步时间较晚,研究成果相对较少且主要集中于样本量较小的I期、II期研究,治疗方案本身存在也许多尚不明确的地方,在获益人群的筛选、治疗周期的选择和疗效预测等方面也尚未达成广泛的共识。本文综述了与新辅助免疫治疗相关的重要研究和新近成果,旨在以这些研究的成果为基础,从获益人群、治疗周期和疗效预测三个方面全方位探讨该类治疗的流程及存在的问题。
The emergence of immune checkpoint inhibitors(ICIs) has dramatically changed the therapeutic outlo ok for patients with non-small cell lung cancer(NSCLC).Preoperative neoadj uvant immunotherapy has been paid more and more attention as an effective and safe treatment.Neoadjuvant immune therapy,however,the relevant research started late,relatively few research results and mainly focused on the small sample size of phase Ⅰ and Ⅱ studies,treatment itself exists many places it is not clear,also in benefit population screening,the respect such as the choice of treatment and curative effect prediction has not yet reached broad consensus.This paper reviews the important studies and recent achievements related to neoadjuvant immunotherapy,aiming to comprehensively discuss the procedures and existing problems of this kind of therapy from three aspects of beneficiary groups,treatment cycle and efficacy prediction.
作者
纪敬斌
张宸瑜
彭垒
矫文捷
Jingbin JI;Chenyu ZHANG;Lei PENG;Wenjie JIAO(Department of Thoracic Surgery,Affiliated Hospital of Qingdao University,Qingdao 266071,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2022年第2期92-101,共10页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
围术期
免疫治疗
新辅助治疗
免疫检查点抑制剂
综述
Lung neoplasms
Perioperative
Immunotherapy
Neoadjuvant therapy
Immune checkpoint inhibitors
Review
